Zhejiang Yatai Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jianwei Cen

İcra Kurulu Başkanı

CN¥507.6k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	2.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Jianwei Cen (52 yo)

less than a year

Görev süresi

CN¥507,600

Tazminat

Mr. Jianwei Cen is General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd. from February 7, 2024. Mr. Cen was Deputy General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd.from April 15, 2022 to Febru...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jianwei Cen	General Manager	less than a year	CN¥507.60k	Veri yok
Jingyang Xu	Financial Director & Accounting Supervisor	2.6yrs	CN¥487.20k	Veri yok
Wei Xu	Board Secretary	2.6yrs	CN¥487.40k	Veri yok
Bao Kun Hu	Deputy General Manager	16.9yrs	CN¥404.00k	Veri yok
Qin Shui Tan	Deputy General Manager	10.9yrs	CN¥453.60k	Veri yok

2.6yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: 002370 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Min Tu	Supervisor	2.7yrs	Veri yok	Veri yok
Xiaoming Huang	Director	2.6yrs	CN¥1.04m	Veri yok
Cai Fu	Vice Chairman of the Board	2.6yrs	Veri yok	Veri yok
Lingbo Song	Non-Independent Director	2.6yrs	Veri yok	Veri yok
Wei Huang	Non-Independent Director	2.6yrs	CN¥359.60k	Veri yok
Yajian Zhou	Non-Independent Director	2.6yrs	CN¥306.20k	Veri yok
Haizhou Lu	Independent Director	2.6yrs	CN¥100.00k	Veri yok
Yuehui Liu	Independent Director	2.6yrs	CN¥100.00k	Veri yok
Lingjie Song	Chairman	2.6yrs	Veri yok	Veri yok
Min Cai	Independent Director	2.6yrs	CN¥100.00k	Veri yok
Huaying Zhou	Supervisor	2.6yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002370 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Zhejiang Yatai Pharmaceutical Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million.

Second quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.049 in 2Q 2023)

New minor risk - Share price stability

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

First quarter 2024 earnings released: CN¥0.005 loss per share (vs CN¥0.005 loss in 1Q 2023)

Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021)

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019)

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

New 90-day high: CN¥5.45

New 90-day low: CN¥3.60

New 90-day low: CN¥4.29

New 90-day low: CN¥4.44

New 90-day low: CN¥4.77

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

New 90-day high - CN¥6.25

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş